PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma
dc.contributor.author | Ross, R.L. | * |
dc.contributor.author | McPherson, H.R. | * |
dc.contributor.author | Kettlewell, L. | * |
dc.contributor.author | Shnyder, Steven D. | * |
dc.contributor.author | Hurst, C.D. | * |
dc.contributor.author | Alder, O. | * |
dc.contributor.author | Knowles, M.A. | * |
dc.date.accessioned | 2016-08-15T09:12:13Z | |
dc.date.available | 2016-08-15T09:12:13Z | |
dc.date.issued | 2016-07-28 | |
dc.identifier.citation | Ross RL, McPherson HR, Ketlewell L, Shnyder SD, Hurst CD, Alder O and Knowles MA (2016) PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer. 16: 553. | en_US |
dc.identifier.uri | http://hdl.handle.net/10454/8800 | |
dc.description | Yes | en_US |
dc.description.abstract | Background: Many urothelial carcinomas (UC) contain activating PIK3CA mutations. In telomerase-immortalized normal urothelial cells (TERT-NHUC), ectopic expression of mutant PIK3CA induces PI3K pathway activation, cell proliferation and cell migration. However, it is not clear whether advanced UC tumors are PIK3CA-dependent and whether PI3K pathway inhibition is a good therapeutic option in such cases. Methods: We used retrovirus-mediated delivery of shRNA to knock down mutant PIK3CA in UC cell lines and assessed effects on pathway activation, cell proliferation, migration and tumorigenicity. The effect of the class I PI3K inhibitor GDC-0941 was assessed in a panel of UC cell lines with a range of known molecular alterations in the PI3K pathway. Results: Specific knockdown of PIK3CA inhibited proliferation, migration, anchorage-independent growth and in vivo tumor growth of cells with PIK3CA mutations. Sensitivity to GDC-0941 was dependent on hotspot PIK3CA mutation status. Cells with rare PIK3CA mutations and co-occurring TSC1 or PTEN mutations were less sensitive. Furthermore, downstream PI3K pathway alterations in TSC1 or PTEN or co-occurring AKT1 and RAS gene mutations were associated with GDC-0941 resistance. Conclusions: Mutant PIK3CA is a potent oncogenic driver in many UC cell lines and may represent a valuable therapeutic target in advanced bladder cancer. | en_US |
dc.language.iso | en | en_US |
dc.relation.isreferencedby | http://dx.doi.org/10.1186/s12885-016-2570-0 | en_US |
dc.rights | © 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | en_US |
dc.subject | PIK3CA; PI3K signaling; Bladder cancer, Urothelium | en_US |
dc.title | PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma | en_US |
dc.status.refereed | Yes | en_US |
dc.date.Accepted | 2016-07-15 | |
dc.type | Article | en_US |
dc.type.version | published version paper | en_US |
refterms.dateFOA | 2018-07-25T15:24:34Z |